Successful translational R&D needs equity ownership

12/6/2012 | Forbes

Early-stage translational research and development projects in life sciences are likely to fall flat in the absence of equity ownership in startup companies, writes Atlas Venture partner Bruce Booth. Equity ownership "rewards the successful entrepreneur and binds them together with the academic founders, key advisors, and the broader shareholders," he writes. Equity rewards risk-takers and entrepreneurs, thus encouraging investment, he writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC